Daily scan of every earnings reaction moving 20% or more, either direction. Ranked within each column by mismatch -- overreactions and mixed calls first, clean justified moves last -- so the ones worth reading first are on top.
CRWV — CoreWeave, Inc. Class A Common Stock (+20.5%)
CoreWeave reported a modest EPS beat of 14.9% (−$1.03 actual vs. −$1.21 estimate) and a marginal revenue beat of 0.8% ($2,575M actual vs. $2,554M estimate), yet the stock rallied 20.5%—a significant disconnect. The real driver appears to be forward momentum metrics: record $104 billion revenue backlog (plus $25 billion in early Q3 commitments), accelerating customer wins, expansion to 1.5 GW active power and 3.7 GW contracted power, and several high-profile strategic wins (Jane Street $1B investment, Nasdaq-100 inclusion, new $3.1B term loan facility). However, on GAAP metrics the picture is darker—operating loss widened to −$49M (from +$19M YoY), net loss margin held flat at −24%, and adjusted operating income margin compressed to 5% from 16% despite 112% revenue growth. The rally appears substantially priced on backlog and technology leadership positioning rather than current profitability, suggesting investors are betting heavily on future operating leverage that hasn't yet materialized in the numbers.
View CRWV →HYLN — Hyliion Holdings Corp. (+30.9%)
Hyliion crushed the top line by 106% (revenue of $4.9M vs. consensus $2.4M estimate) and reported a modest EPS miss of 5.7%, but the headline miss obscures explosive business momentum. The company landed a $41.7M U.S. Navy contract—its largest military deal ever—and raised full-year 2026 revenue guidance 50% to $15M, while management telegraphed expectations for nearly $50M in total new military funding by year-end 2026. Beyond the near-term revenue lift, the press release showcases tangible progress on three long-term value drivers: a 3x potential improvement in additive manufacturing throughput, a capital-efficient manufacturing model requiring $1.5M per megawatt of annual capacity, and accelerating data center demand now discussed at 'tens to hundreds of megawatts' scale with 750 non-binding LOIs already in hand. The +31% move is substantially justified by the confluence of a massive revenue beat, a 50% guidance raise, a landmark military contract, and de-risked manufacturing economics—not just a single metric but a fundamental de-risking of execution and addressable market size.
View HYLN →VELO — Velo3D, Inc. (+22.4%)
Velo3D delivered a revenue beat of 46% ($20.7M actual vs. $14.1M estimate) with 52% year-over-year growth, while also posting a smaller-than-expected loss on a non-GAAP basis ($0.30 actual vs. $0.2675 estimate, though the GAAP miss was -12.1%). Beyond the quarterly beat, management raised full-year 2026 guidance to $65–75M from $60–70M, upgraded gross margin guidance to >30% in H2 2026, and promised positive EBITDA in H2—all while reporting a strengthened balance sheet with $91.1M cash (up from $39M end-2025), reduced debt by over 70% to $8.2M, and a transformational capacity expansion (Livermore campus expected to triple manufacturing capacity and launch later in 2026). The company also secured $29M in new bookings in Q2 with $31M backlog, expanded strategic partnerships (Mears' fifth order, Aurelia Technologies deal), and made market-structure improvements (Russell 3000 inclusion). A 22% rally on a 46% revenue beat, material margin and guidance improvements, debt reduction, and capacity-doubling catalysts is proportionate to the operational and financial inflection the company is executing.
View VELO →NCMI — National CineMedia, Inc. (-27.4%)
National CineMedia reported Q2 revenue of $58.4M, a 12.7% year-over-year increase and essentially in line with the $59.34M estimate (slight miss of ~1.5%), but the company swung to a GAAP net loss of $0.11 per share versus an expected loss of $0.085 per share—an 17.6% negative surprise. On the surface, the operational business showed strength: adjusted OIBDA improved to $2.1M from $0.7M, attendance rose 19%, and management executed $2.7M in cost savings while guiding toward $11M annualized savings. However, the stock's 27% plunge reflects two major headwinds beyond the modest earnings miss: (1) NCM announced a transformative $275M acquisition of Captivate funded entirely by new debt, dramatically increasing leverage and near-term financial risk, and (2) the company suspended its quarterly dividend and withdrew forward guidance due to pending transaction uncertainty. The earnings beat/miss itself is too small to justify a quarter-drop of this magnitude, but the acquisition announcement, debt load, dividend suspension, and lack of visibility on deal completion timing created a perfect storm of negative catalysts. A 27% decline following a modest EPS miss coupled with a leveraged M&A deal and dividend cut appears partially justified, though the acquisition's promised $3.5M in cost synergies and underlying business momentum suggest the market may be pricing in excessive execution risk.
View NCMI →SLXN — Silexion Therapeutics Ltd. (-58.8%)
Silexion reported no quantified earnings or revenue figures in its August 11, 2026 earnings materials—only a Phase 2/3 clinical trial initiation for SIL204 in locally advanced pancreatic cancer (LAPC), announced in July 2026 with regulatory approvals in Israel and Germany, plus preclinical efficacy data and a planned FDA pre-IND meeting for early 2027. As a development-stage biotech with zero revenue and no marketed products, the company has no traditional EPS or revenue metrics to beat or miss. The 58.8% stock collapse cannot be benchmarked against earnings surprises because there were none; instead, the move likely reflects disappointment with trial design details (small initial cohorts of 15–18 patients in Segment 1, with primary endpoints not due until Q2 2027 for early data and 2028 for interim results), competitive positioning concerns, or broader biotech sector headwinds unrelated to the earnings call itself. Without disclosed actual vs. consensus estimates, guidance revisions, or material clinical setbacks in the release, the magnitude of the decline appears disconnected from the substance of what was announced—making this either an overreaction to trial timeline delays or a response to undisclosed commentary during the call.
View SLXN →SNAL — Snail, Inc. Class A Common Stock (-28.1%)
Snail Inc. reported a catastrophic earnings miss on August 11, 2026, with EPS of -$0.36 versus consensus estimates of $1.55—a 123.2% negative surprise—and revenue of $19.7 million versus the $29.0 million expected, representing a 32.2% shortfall. The company swung from an expected profit of $1.55 per share to a loss, signaling fundamental operational distress rather than a minor execution miss. A 28.1% stock decline on an earnings report of this magnitude—missing both the top and bottom lines by roughly one-third and flipping from profitability to losses—reflects appropriate repricing of shareholder value given the scale of the disappointment. The severity of the miss, particularly the swing to negative earnings, justifies substantial single-day losses as investors recalibrate risk and growth assumptions for the company.
View SNAL →